Kinnate Biopharma Inc. (KNTE) Financials
Stock symbol KNTE is outdated, potentially delisted? Maybe it is available on other exchange?
KNTE Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| Sept. 30, 2023 | 190.7 million | 18.3 million |
| June 30, 2023 | 216.1 million | 18.5 million |
| March 31, 2023 | 243.9 million | 21.1 million |
| Dec. 31, 2022 | 278.8 million | 20.4 million |
KNTE Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| Sept. 30, 2023 | -25.5 million | 5.3 million |
| June 30, 2023 | -29.4 million | 5.4 million |
| March 31, 2023 | -27.7 million | 5.4 million |
| Dec. 31, 2022 | -23.8 million | 4.9 million |
KNTE Net Income
No data available :(
KNTE Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| Sept. 30, 2023 | 167.6 million | - | 3.4 million |
| June 30, 2023 | 184.7 million | - | 3.7 million |
| March 31, 2023 | 201.0 million | - | 3.9 million |
| Dec. 31, 2022 | 201.5 million | - | 4.2 million |
KNTE Shares Outstanding
KNTE Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| Sept. 30, 2023 | - | 24.5 million | 6.6 million | - |
| June 30, 2023 | 9000 | 26.3 million | 7.8 million | - |
| March 31, 2023 | 9000 | 26.6 million | 8.1 million | - |
| Dec. 31, 2022 | 90000 | 25.2 million | 7.5 million | - |
KNTE Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| Sept. 30, 2023 | - | 197000 |
| June 30, 2023 | - | 201000 |
| March 31, 2023 | - | 203000 |
| Dec. 31, 2022 | - | 190000 |
KNTE
Price: $2.65
52 week price:
Earnings Per Share: -2.78 USD
P/E Ratio: -0.84
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 55200
Market Capitalization: 125.0 million